![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FCGR3A |
Gene summary for FCGR3A |
![]() |
Gene information | Species | Human | Gene symbol | FCGR3A | Gene ID | 2214 |
Gene name | Fc fragment of IgG receptor IIIa | |
Gene Alias | CD16 | |
Cytomap | 1q23.3 | |
Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | M9MML0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2214 | FCGR3A | HCC1_Meng | Human | Liver | HCC | 1.23e-06 | -5.55e-02 | 0.0246 |
2214 | FCGR3A | Pt13.a | Human | Liver | HCC | 6.34e-09 | 2.67e-01 | 0.021 |
2214 | FCGR3A | Pt13.c | Human | Liver | HCC | 7.87e-11 | 6.17e-01 | 0.0076 |
2214 | FCGR3A | Pt14.d | Human | Liver | HCC | 5.55e-20 | 6.08e-01 | 0.0143 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | CRC | ![]() |
Stomach | GC | ![]() |
Stomach | CAG with IM | ![]() |
Stomach | CSG | ![]() |
Stomach | CAG | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0414521 | Liver | HCC | Phagosome | 93/4020 | 152/8465 | 4.27e-04 | 1.88e-03 | 1.05e-03 | 93 |
hsa0466610 | Liver | HCC | Fc gamma R-mediated phagocytosis | 58/4020 | 97/8465 | 9.65e-03 | 2.52e-02 | 1.40e-02 | 58 |
hsa0414531 | Liver | HCC | Phagosome | 93/4020 | 152/8465 | 4.27e-04 | 1.88e-03 | 1.05e-03 | 93 |
hsa0466611 | Liver | HCC | Fc gamma R-mediated phagocytosis | 58/4020 | 97/8465 | 9.65e-03 | 2.52e-02 | 1.40e-02 | 58 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FCGR3A | SNV | Missense_Mutation | novel | c.548N>A | p.Gly183Asp | p.G183D | protein_coding | tolerated(0.05) | probably_damaging(0.978) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
FCGR3A | SNV | Missense_Mutation | novel | c.716N>C | p.Phe239Ser | p.F239S | protein_coding | tolerated(0.14) | benign(0.03) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
FCGR3A | SNV | Missense_Mutation | rs370288605 | c.163N>T | p.Arg55Trp | p.R55W | protein_coding | deleterious(0.01) | possibly_damaging(0.655) | TCGA-AZ-4323-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | PD | |
FCGR3A | SNV | Missense_Mutation | c.479N>G | p.Ile160Ser | p.I160S | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | ||
FCGR3A | SNV | Missense_Mutation | rs778260076 | c.451N>T | p.Arg151Trp | p.R151W | protein_coding | deleterious(0) | possibly_damaging(0.842) | TCGA-DM-A1D4-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
FCGR3A | SNV | Missense_Mutation | rs749283416 | c.401A>G | p.Asp134Gly | p.D134G | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
FCGR3A | SNV | Missense_Mutation | rs778260076 | c.451N>T | p.Arg151Trp | p.R151W | protein_coding | deleterious(0) | possibly_damaging(0.842) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
FCGR3A | SNV | Missense_Mutation | rs142959418 | c.220N>T | p.Leu74Phe | p.L74F | protein_coding | tolerated(0.08) | probably_damaging(1) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
FCGR3A | SNV | Missense_Mutation | novel | c.444N>T | p.Gln148His | p.Q148H | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
FCGR3A | SNV | Missense_Mutation | c.77N>A | p.Ser26Tyr | p.S26Y | protein_coding | deleterious(0.04) | possibly_damaging(0.804) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2214 | FCGR3A | EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | PROTEASE INHIBITORS | 16103765 | ||
2214 | FCGR3A | EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | LIF | 7686393 | ||
2214 | FCGR3A | EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | CYCLOSPORINE | CYCLOSPORINE | 17852453 | |
2214 | FCGR3A | EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | ANGIOGENESIS INHIBITOR | 15457133 | ||
2214 | FCGR3A | EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | H2O2 | 2138680 | ||
2214 | FCGR3A | EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | BRM | 1832500 | ||
2214 | FCGR3A | EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | INDOMETHACIN | INDOMETHACIN | 17329922 | |
2214 | FCGR3A | EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | IL-8 | 1827816 | ||
2214 | FCGR3A | EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | FLT3L | 15102482 | ||
2214 | FCGR3A | EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | RECOMBINANT STEM CELL FACTOR | 10432289 |
Page: 1 2 3 4 5 6 |